Edesa Biotech (EDSA) Receivables - Other (2021 - 2022)
Edesa Biotech (EDSA) posted Receivables - Other of $1.1 million for Q3 2022, little changed sequentially from $1.1 million in Q2 2022, and down 63.7% YoY from $3.0 million in Q3 2021.
Edesa Biotech (EDSA) Receivables - Other (2021 - 2022) Analysis & Trends
Edesa Biotech has reported Receivables - Other for 2 years, with the latest figure at $1.1 million in Q3 2022.
- Quarterly Receivables - Other fell 63.7% year-over-year to $1.1 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $1.1 million (down 63.7% YoY) and the FY2022 annual result came in at $1.1 million, down 63.7% from the prior year.
- Receivables - Other held at $1.1 million in Q3 2022 per EDSA's latest filing, from $1.1 million in the prior quarter.
- Over five years, Receivables - Other peaked at $4.0 million in Q2 2021 and troughed at $1.1 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Edesa Biotech | 43.15 Mn | 43.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 1.10 Mn |
| Sep 30, 2022 | 1.10 Mn |
| Jun 30, 2022 | 1.10 Mn |
| Jun 30, 2022 | 1.10 Mn |
| Mar 31, 2022 | 1.10 Mn |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 2.63 Mn |
| Dec 31, 2021 | 2.63 Mn |
| Sep 30, 2021 | 3.03 Mn |
| Sep 30, 2021 | 3.03 Mn |
| Jun 30, 2021 | 3.99 Mn |
| Jun 30, 2021 | 3.99 Mn |